In lung cancer, mutated KRAS is a hallmark of non-small cell lung cancer (NSCLC), particularly adenocarcinoma, where it promotes tumor development and progression (Ferrer et al. 2018). This evidence concerns the gene KRAS and non-small cell lung carcinoma.